Results 11 to 20 of about 1,288,674 (265)

Drug Resistance in Leishmaniasis [PDF]

Journal of Global Infectious Diseases, 2010
The treatment options of leishmaniasis are limited and far from satisfactory. For more than 60 years, treatment of leishmaniasis has centered around pentavalent antimonials (Sb(v)). Widespread misuse has led to the emergence of Sb(v) resistance in the hyperendemic areas of North Bihar. Other antileishmanials could also face the same fate, especially in
Jaya Chakravarty, Shyam Sundar
openaire   +3 more sources

Drivers and sites of diversity in the DNA adenine methylomes of 93 Mycobacterium tuberculosis complex clinical isolates

eLife, 2020
This study assembles DNA adenine methylomes for 93 Mycobacterium tuberculosis complex (MTBC) isolates from seven lineages paired with fully-annotated, finished, de novo assembled genomes. Integrative analysis yielded four key results.
Samuel J Modlin, Derek Conkle-Gutierrez, Calvin Kim, Scott N Mitchell, Christopher Morrissey, Brian C Weinrick, William R Jacobs, Sarah M Ramirez-Busby, Sven E Hoffner, Faramarz Valafar   +9 more
doaj   +1 more source

Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma

Pharmaceuticals, 2021
Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors worldwide. The diagnosis is often possible only in the latter stages of the disease, with patients already presenting an advanced or metastatic tumor. It is also one of the
Rita Rebelo, Bárbara Polónia, Lúcio Lara Santos, M. Helena Vasconcelos, Cristina P. R. Xavier   +4 more
doaj   +1 more source

Survival outcomes of autologous breast reconstruction after mastectomy: A matched case-control study

Frontiers in Oncology, 2023
BackgroundDue to the lack of strong evidence-based medical evidence, the relationship between autologous breast reconstruction (ABR) after mastectomy and long-term prognosis is unclear.
Shang Wu, Shang Wu, Xindi Ma, Xindi Ma, Xiangmei Zhang, Xiangmei Zhang, Chao Yang, Chao Yang, Yubin Wang, Yubin Wang, Yunjiang Liu, Yunjiang Liu   +11 more
doaj   +1 more source

Drug resistance and combating drug resistance in cancer

Cancer Drug Resistance, 2019
Cancer is the second leading cause of death in the US. Current major treatments for cancer management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy, endocrine therapy and immunotherapy. Despite the endeavors and achievements made in treating cancers during the past decades, resistance to classical chemotherapeutic agents ...
Wang, Xuan, Zhang, Haiyun, Chen, Xiaozhuo   +2 more
openaire   +3 more sources

Drug resistant tuberculosis [PDF]

BMJ, 1995
EDITOR,—Concern is growing over the spread of drug resistant Mycobacterium tuberculosis. New evidence suggests that this spread may be increasing in certain sections of the British population. The recent advances in molecular techniques have equipped us with the means to make substantial inroads into the possible impact of drug resistant tuberculosis.1
openaire   +4 more sources

Multiplex CRISPRi System Enables the Study of Stage-Specific Biofilm Genetic Requirements in Enterococcus faecalis

mBio, 2020
Enterococcus faecalis is an opportunistic pathogen, which can cause multidrug-resistant life-threatening infections. Gaining a complete understanding of enterococcal pathogenesis is a crucial step in identifying a strategy to effectively treat ...
Irina Afonina, June Ong, Jerome Chua, Timothy Lu, Kimberly A. Kline   +4 more
doaj   +1 more source

The Value of Neutrophil Gelatinase-Associated Lipocalin Receptor as a Novel Partner of CD38 in Chronic Lymphocytic Leukemia: From an Adverse Prognostic Factor to a Potential Pharmacological Target?

Biomedicines, 2023
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic B lymphocytes that escape death, and correlates with the expression of negative prognostic markers such as the CD38 antigen.
Brigitte Bauvois, Elise Chapiro, Claire Quiney, Karim Maloum, Santos A. Susin, Florence Nguyen-Khac   +5 more
doaj   +1 more source

Rv1453 is associated with clofazimine resistance in Mycobacterium tuberculosis

Microbiology Spectrum, 2023
Clofazimine (CFZ) has been repurposed for treating tuberculosis (TB), especially multidrug-resistant tuberculosis (MDR-TB). However, the mechanisms of resistance to clofazimine are poorly understood.
Lei Zhang, Ye Zhang, Yuanyuan Li, Fengmin Huo, Xi Chen, Hui Zhu, Shaochen Guo, Lei Fu, Bin Wang, Yu Lu   +9 more
doaj   +1 more source

Management of drug resistant tuberculosis: isoniazid resistant, rifampicin resistant, multi drug resistant, and extensively drug resistant

Journal of Lung, Pulmonary & Respiratory Research, 2022
Mycobacterium tuberculosis strains that are resistant to an elevating number of second-line medicines used to treat multidrug-resistant tuberculosis are becoming a threat to public health worldwide. Recent guidelines recommended at least 20 months of treatment, but recent regimens are toxic, poorly tolerated and insufficiently effective, with cure ...
openaire   +1 more source